Committed to quality generics since 1993, Greenstone has a robust and expanding pipeline of innovator-authorized generics and ANDA generic products. Our authorized generics are manufactured under the brand NDAs. Tablets and capsules are the same size, shape, and color as the brand, and are backed with state-of-the-art distribution and customer service support of one of the world’s largest pharmaceutical companies. The expanding line of Greenstone ANDA products covers a broad range of therapeutic areas.
Experience and Commitment
Greenstone leverages decades of experience, dedicated people, and a broad product portfolio that benefits patients, pharmacists, physicians, and our partners. We are deeply committed to product quality and supply and strive to be the industry generic supplier of choice based on the ethics we uphold and the values we deliver.
Recently Added Products
Greenstone LLC recently announced the addition of latanoprost and exemestane to its generic pharmaceutical product portfolio.
Latanoprost is the authorized generic of, and thereby fully substitutable for, Xalatan® (latanoprost). This generic product from Greenstone is being offered in 125 mg/2.5 mL solution, available in single count and 3-count cartons. Exemestane is the authorized generic of, and thereby fully substitutable for, Aromasin® (exemestane). This generic product from Greenstone is being offered in 25-mg tablets, available in bottles of 30 tablets.
Latanoprost and exemestane, which complement the growing line of products from Greenstone, are supported by a company heritage of quality, reliable manufacturing, and customer-focused attention.
Xalatan (latanoprost) and Aromasin (exemestane) are registered trademarks of Pfizer Inc. PT
For more information, visit www.GreenstoneLLC.com.
GREENSTONE L L C Greenstone LLC recently announced the addition of latanoprost and exemestane to its generic pharmaceutical product portfolio.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs